You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In two trials in the neoadjuvant setting reported at SABCS, one showed improved rates of pathologic complete response with added immunotherapy, and the other showed no difference.
New data on Kadcyla and Tecentriq will help doctors further refine precision medicine options for breast cancer patients with unmet needs.
Researchers showed, retrospectively, that using a cutoff of 16 circulating DNA mutations they could identify patients who were more likely to respond to immunotherapy.
The company shared validation data this week that it said led the FDA to approve use of the test in a new prospective trial of Roche's Tecentriq in NSCLC.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.